Board of Directors
Tim Hoerr, CPA, CMA
Tim Hoerr is a seasoned business executive with over 30 years of experience in a variety of industries. He serves as the CEO and President of Serra Ventures, a consultancy offering professional services to emerging technology enterprises, and Principal of Serra Capital, a firm providing seed, emerging and growth capital to high technology companies. Tim has worked in the University of Illinois at Urbana-Champaign (“UIUC”) technology community since 2001 and is a charter member of the University’s Entrepreneur-in-Residence program at EnterpriseWorks business incubator in the Research Park. He was co-founder and former CEO of iCyt Mission Technology, Inc., a highly successful bio-instrument company that has won numerous awards for technology and business excellence and which was acquired by Sony Corporation in late 2009. Tim was awarded the Entrepreneurial Excellence in Management Award at the Innovation Celebration, 2009. Since 1983 he has assisted over 500 organizations to achieve high performance by providing strategic, operational and leadership consulting. Tim spent nearly all of the first 15 years of his professional career with RSM McGladrey in Illinois and San Diego, leading teams of consultants focused on serving middle market clients. In his capacity as Consulting Partner with McGladrey, Tim provided leadership on a regional and national level. He also served on two national committees for the American Society of Certified Public Accountants (Business Valuation and Emerging Services). Also a professional author and speaker, he has given over 300 speaking and workshop presentations in his professional career to such diverse groups as Nabisco, Buck Knives, SaabCars USA, and Nationalease. Tim holds the Certified Public Accountant (CPA, 1983) and Certified Management Accountant (CMA, 1984) designations. He received national honors on both the CPA and CMA examinations. He formerly held the Accredited Senior Appraiser of Business Valuation credential (American Society of Appraisers) while actively practicing business valuation as a partner in RSM McGladrey. Mr. Hoerr has a B.S. in Accounting and a B.S. in Business Admin. From Illinois State University, summa cum laude, graduating in 1983. Mr. Hoerr is on the boards of Baylor University Technology Entrepreneurship Initiative (2009 to present), Urbana-Champaign Angel Network (Chairman, 2010 to present), Vineyard Church Pastoral Advisory Council (2012 to present), and Champaign County Economic Development Corporation (2004 to 2012).
As an industry veteran with extensive investment and operational experience, Nina Saberi brings deep business expertise and hands-on management experience to a new generation of impactful entrepreneurial businesses. Ms. Saberi currently serves on the boards of Agiliance, Connotate, Funambol, and Nanomedical Diagnostics operating in the mobile/enterprise infrastructure, Cloud, security, and life science markets. Ms. Saberi joined the venture community as a general partner at OneLiberty Ventures. She then founded Castile Ventures where, under her leadership, Castile raised hundreds of millions of dollars in multiple funds and partnered with innovative and successful entrepreneurs to become a highly respected top ranking early stage Venture firm. Ms. Saberi served many of the portfolio companies as the chairman of the board, founding VC, lead director or investor. These companies are now public (Sonus Networks), or operating as part of acquiring companies including: Thermo Fisher (Ahura Scientific), Symantec/PGP (ChosenSecurity), EMC (Network Intelligence), NetScout (Quantiva), Belden (Trapeze Networks), Pace (Aurora Networks), VeriSign (GeoTrust), Vecna (VGo Communications), thinkingphones (Whaleback), C-Cor (Stargus), Logility (Optiant), and EXFO (Brix).During her operating career, Ms. Saberi was president and CEO of venture-backed Netlink, which was acquired by Cabletron as one of the top three acquisitions of its year. She also successfully led Amnet to its acquisition, managed an international joint venture for Data General and Singapore Telecom and held executive marketing and engineering positions at BBN and Avanti Communications. In 2010, Ms. Saberi was recognized by AlwaysOn as one of the top VCs in the East, and in 2006 by Mass High Tech as an All Star in Finance. She is the Chairman Emeritus of the Massachusetts Technology Leadership Council (formerly known as the Massachusetts Network Communications Council) and has served on the President’s Advisory Council at the University of Rhode Island where she received her BS in Electrical Engineering. In 2007, URI honored Ms. Saberi with the President’s Distinguished Achievement Award.
Joseph D. Keegan, PH.D.
Dr. Keegan has more than 30 years of experience in life science businesses. As CEO at ForteBio, Inc. he led the Series C financing which raised $25M, established product development and sales strategies that resulted in 2007-11 compounded annual revenue growth of 45% to $27M , and exited the company in 2012 through its sale to Pall Corporation for a return to investors of $160M. During his 9 year tenure as CEO at Molecular Devices Corporation, Dr. Keegan grew the company’s revenues from $30M to $185M through internal growth and acquisitions. In early 2007, he oversaw its acquisition by MDS Corporation for $615M. Dr. Keegan joined MDC from Becton Dickinson and Company where he served as President of Worldwide Tissue Culture and Vice President, General Manager of Worldwide Flow Cytometry. Prior to Becton Dickinson, Dr. Keegan was Vice President of the Microscopy and Scientific Instruments Division of Leica, Inc. He currently serves on the Boards of Directors of Courtagen Life Sciences, Interpace Diagnostics Inc. (NASDAQ: IDGX), Labcyte Corporation as Chairman, Optofluidics, Inc., Response Biomedical Corporation (RBM:Toronto), Unchained Labs, Inc., Wasatch Microfluidics, Inc., and the San Francisco Opera. Dr. Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.
Brett Goldsmith, Ph.D.
A founding member of Nanomedical Diagnostics and the company’s CTO, Dr. Goldsmith’s passion is taking nanoelectronic technology out of the theoretical realm to create practical products. One of the few people in the world with the combined expertise in biology and nanotechnology needed to develop graphene as a viable bio-electronic device, Dr. Goldsmith was the lead researcher on landmark field effect biosensing papers in Science and Nature Nanotechnology. His early work established coupling of biochemical systems to carbon nanotubes, for which he won the Nottingham Prize from the Physical Electronics Conference. Following graduate school at UC Irvine, Dr. Goldsmith joined the University of Pennsylvania as an Intelligence Community Fellow and led a project developing electronic devices coupled with GPCRs for multiplexed small molecule sensing. Leaving his post-doc position to start a nanotechnology group at the Navy’s San Diego laboratory, Dr. Goldsmith identified technological needs in the field and advanced nanotechnology solutions to those needs through partnership with programs including Living Foundries and IVN Dx. Dr. Goldsmith brings proven experience in applying technological advancements in materials and electronics to biomedical needs.
A founding member of Nanomedical Diagnostics and the company’s CEO, Ross is a graduate of UCSD with an MBA from SDSU. Ross’s passion is precision execution, and he applies this to driving company direction and operations, raising capital funding, and developing strategic collaborations and partnerships. Ross brings business development, supply chain, finance, and operations expertise from 13 years of experience in industries ranging from consumer goods to defense manufacturing to financial services. At Bumble Bee Foods, Ross created and implemented cross-functional supply chain procedures that reduced processing hours while improving scheduling accuracy and decreasing cost. Prior to Bumble Bee at General Dynamics, Ross identified and negotiated business development projects that gained the company new opportunities in alternative energy, commercial construction, and heavy tool manufacturing. At UBS Financial Services, Ross created financial models to estimate future growth rates. Ross brings a demonstrated track record of successful implementation and a well-rounded background to his role as CEO of Nanomedical Diagnostics.